CV Sciences Inc logo

CVSI - CV Sciences Inc News Story

$0.145 0.0  3.6%

Last Trade - 8:12pm

Sector
Healthcare
Size
Micro Cap
Market Cap £11.5m
Enterprise Value £10.3m
Revenue £15.0m
Position in Universe 6727th / 7414

CV Sciences, Inc. Appoints Haskell & White LLP as Auditor

Tue 30th November, 2021 9:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211130:nGNX7BqcLk&default-theme=true


SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI)
(the “Company”, “CV Sciences”, “our”, “us” or “we”), a
preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today
announced that it has appointed Haskell & White LLP ("H&W") as the Company's
new independent registered public accounting firm.

"Following a thorough selection process, the Company's Audit Committee has
concluded that H&W is best positioned to meet the evolving needs of CV
Sciences. This is the result of our ongoing efforts to implement cost
efficiencies to fully leverage our business model. We would like to thank
Deloitte & Touche LLP for their quality work and expertise they have provided
over the last two years," said Joseph Dowling, Chief Executive Officer of CV
Sciences.

The Company has also filed a Form 8-K with the Securities and Exchange
Commission noting the engagement of H&W.

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a
consumer product division focused on manufacturing, marketing and selling
plant-based dietary supplements and CBD products to a range of market sectors;
and a drug development division focused on developing and commercializing
CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at
more than 7,700 retail locations throughout the U.S. and it is one of the
top-selling brands of hemp-derived CBD in the natural products market,
according to SPINS, the leading provider of syndicated data and insights for
the natural, organic and specialty products industry. CV Sciences follows all
guidelines for Good Manufacturing Practices (GMP) and the Company’s products
are processed, produced, and tested throughout the manufacturing process to
confirm strict compliance with company standards and specifications. With a
commitment to science, PlusCBD™ product benefits in healthy people are
supported by human clinical research data, in addition to three published
clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp
CBD supplement brand to invest in the scientific evidence necessary to receive
self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc.
has primary offices and facilities in San Diego, California. Additional
information is available from OTCMarkets.com or by visiting
www.cvsciences.com. 

Forward Looking Statements
This press release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties. Such
forward-looking statements by definition involve risk and uncertainties.

Contact Information

Investor Contact:
ICR
Reed Anderson
646-277-1260
reed.anderson@icrinc.com 

Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com 


(https://www.globenewswire.com/NewsRoom/AttachmentNg/b6d24907-4648-4d59-b927-204cc32d3b67)



GlobeNewswire, Inc. 2021
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.